Myeloma UK news
The need to improve treatment and care for people with blood cancers like myeloma, and the work of Myeloma UK, has been highlighted in the first report by Westminster’s cross-party group on blood cancer.
The results from this trial show that antibiotic prophylaxis with levofloxacin may improve the quality of life and outcomes of newly diagnosed myeloma patients by reducing the risk of infection and early death, without increasing the risk of developing antibiotic resistance and hospital-acquired infections.
Myeloma UK has had another successful year of Infodays, with 12 events held across the UK and over 1,250 people attending. 2017 also saw the very first Carer and Family Infoday in Newcastle, the first event of its kind.
Talented young artist Molly from Ealing, London has designed this year’s Christmas e-card for supporters who are donating to Myeloma UK instead of giving Christmas cards or presents. The artistic seven-year-old supports Myeloma UK in memory of her grandmother who passed away from myeloma in 2011.
Highlights from the American Society of Hematology (ASH) conference 2017 being attended by Myeloma UK Chief Executive Rosemarie Finley and Director of Research, Dr Simon Ridley.
Myeloma UK has recently had their Patient Information certified by The Information Standard, a health and care certification programme supported by NHS England. The accreditation signifies that the information provided by Myeloma UK is reliable, accurate and of high quality.
The Myeloma Early Diagnosis Working Group held their final meeting of the year earlier this month in London. The Group was established in late 2016 and consists of a panel of leading haematologists, primary healthcare professionals (such as GPs) and researchers.
A new patient preference study has been published in The Oncologist, providing insight into how myeloma patients rationalise treatments.
Leaving a gift in your Will is a great way to support causes that matter to you. Last year, we received £710,000 in donations from Wills which funded services for patients and families, as well as vital myeloma research.
Myeloma UK has launched MUK nine, the first UK-wide trial using state-of-the-art genetic techniques to ‘stratify’ treatment for so-called high-risk myeloma patients.